Exchange: NASDAQ·Updated 07:06 PM EDT
News
all
press releases
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
More News
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
Omeros (OMER) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Dow, Nasdaq, S&P 500 Futures: How Markets Are Trading After July CPI As More Inflation Data Looms
U.S. July CPI broadly met expectations, with headline inflation rising 0.1% month over month and 3.4% year over year, while core CPI increased 0.2% monthly and 2.5% annually.
Stocktwits
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates
Omeros (OMER) delivered earnings and revenue surprises of +107.41% and +130.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
OMER Stock Soars 24% After-Hours On YARTEMLEA Sales Momentum, Debt Reduction And Share Buybacks
Gross revenues from YARTEMLEA reached $32.2 million in the quarter, nearly triple the $11.1 million recorded in the first quarter.
Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved upwards byread more...
Benzinga
Omeros Corporation Reports Second Quarter 2026 Financial Results
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA, the first and only approved treatment for stem cell transplant-associated...
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to...
Business Wire
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug
Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said.
Stocktwits

Advertisement|Remove ads.